Protein characterisation specialist ProtaGene has announced a partnership with the Life Science business of Merck to create an end-to-end testing solution across the whole biopharmaceutical product lifecycle, from early-stage development through to GMP release testing.
The partnership will combine ProtaGene's expertise in advanced protein characterisation and early-stage drug product characterisation with Merck's BioReliance established GMP testing capabilities and global regulatory experience.
The pair stated that they will offer customers a "comprehensive, high-quality offering tailored to the complex demands of modern biologic drug development."
"This strategic partnership brings together highly complementary capabilities and a shared commitment to scientific excellence," said Dr Roland Moussa, President of ProtaGene.
Together with Merck's BioReliance Contract Testing Services, we can offer customers a more integrated path from advanced protein characterisation to global safety and release testing.
"Biopharmaceutical companies need support across the entire development journey, not just at individual stages," added Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck.
By combining ProtaGene's protein characterisation expertise with our BioReliance testing infrastructure, we are providing customers with comprehensive, end-to-end testing solutions to move faster from early development to commercialisation.
In a statement, the duo said the collaboration will aim to help biopharmaceutical companies streamline early-stage development pathways and reduce operational complexity while still maintaining quality and regulatory compliance standards.
Customers can expect to benefit from "coordinated project management, aligned scientific expertise and access to a broader global testing network."